Target Name: CD33
NCBI ID: G945
Review Report on CD33 Target / Biomarker Content of Review Report on CD33 Target / Biomarker
CD33
Other Name(s): gp67 | sialic acid binding Ig-like lectin 3 | CD33 molecule, transcript variant X1 | SIGLEC-3 | CD33 variant X1 | Myeloid cell surface antigen CD33 (isoform 1) | Myeloid cell surface antigen CD33 (isoform X1) | CD33 molecule transcript | CD33_HUMAN | Sialic acid-binding Ig-like lectin 3 | p67 | CD33 molecule | Gp67 | Myeloid cell surface antigen CD33 (isoform 2) | Myeloid cell surface antigen CD33 | Myeloid cell surface antigen CD33 precursor | Sialic acid binding Ig-like lectin 3 | CD33 molecule, transcript variant 2 | Siglec-3 | SIGLEC3 | CD33 variant 1 | P67 | CD33 antigen (gp67) | CD33 variant 2 | sialic acid-binding Ig-like lectin 3 | CD33 molecule, transcript variant 1

CD33 (gp67) as a Potential Drug Target and Biomarker in Cancer: Implications for Targeted Therapies

Introduction

Cancer is a leading cause of morbidity and mortality worldwide, with over 80% of cancer deaths occurring in developed countries. The development of new therapeutic approaches to treat cancer has become a major focus in cancer research in recent years. One of the promising strategies is the use of drugs that target specific proteins involved in cancer growth and progression. One such protein is CD33 (gp67), which is a key regulator of the cell cycle and has been implicated in various cancer processes. In this article, we will explore the potential of CD33 as a drug target and biomarker in cancer, and discuss its implications for targeted therapies.

CD33: Structure and Function

CD33 is a 22kDa protein that is expressed in various tissues, including human tissues, mouse tissues, and human cancer cells. It is a member of the T-cell antigen 6 (TCA6) family and is involved in the development and maintenance of T- cell identity and function. CD33 has been shown to play a critical role in regulating the cell cycle by controlling the entry of new DNA into the cell, thereby influencing the expression of genes involved in cell growth and differentiation.

CD33 has also been shown to be involved in the regulation of cell adhesion and migration. It has been shown to interact with various adhesion molecules, including E-cadherin, N-cadherin, and vimentin, and is involved in the regulation of their distribution and activity.

In addition to its role in cell cycle and adhesion, CD33 has also been implicated in the regulation of apoptosis, a critical process involved in cancer progression. It has been shown to play a role in the regulation of cell apoptosis and has been shown to be involved in the development of resistance to chemotherapy in cancer cells.

CD33 as a Drug Target

The potential of CD33 as a drug target is based on its involvement in various cellular processes that are involved in cancer growth and progression. One of the key strategies for targeting CD33 is the use of small molecules that can inhibit its function.

Several small molecules have been shown to be potential CD33 inhibitors. For example, research has shown that inhibitors of the CD33-Fc domain, which is the portion of the protein that interacts with other proteins, can be effective in inhibiting CD33 function. Additionally, inhibitors of the CD33-CTD domain, which is the portion of the protein that interacts with DNA, have also been shown to be effective in inhibiting CD33 function.

Another approach to targeting CD33 is the use of monoclonal antibodies (mAbs), which are laboratory-produced molecules that recognize and bind to specific proteins. MAbs have been shown to be effective in targeting CD33 and have been used in various clinical trials to treat cancer.

CD33 as a Biomarker

CD33 has also been shown to be a potential biomarker for cancer. The expression of CD33 has been shown to be associated with various types of cancer, including breast, lung, and ovarian cancer. Additionally, research has shown that the expression of CD33 is involved in the development of cancer stem cells, which are a critical step in the development of cancer.

In conclusion, CD33 is a protein that is involved in various cellular processes that are involved in cancer growth and progression. The potential of CD33 as a drug target and biomarker makes it an attractive target for cancer therapies. Further research is needed to fully understand the role of CD33 in cancer and to develop effective therapies that target its

Protein Name: CD33 Molecule

Functions: Sialic-acid-binding immunoglobulin-like lectin (Siglec) that plays a role in mediating cell-cell interactions and in maintaining immune cells in a resting state (PubMed:10611343, PubMed:15597323, PubMed:11320212). Preferentially recognizes and binds alpha-2,3- and more avidly alpha-2,6-linked sialic acid-bearing glycans (PubMed:7718872). Upon engagement of ligands such as C1q or syalylated glycoproteins, two immunoreceptor tyrosine-based inhibitory motifs (ITIMs) located in CD33 cytoplasmic tail are phosphorylated by Src-like kinases such as LCK (PubMed:28325905, PubMed:10887109). These phosphorylations provide docking sites for the recruitment and activation of protein-tyrosine phosphatases PTPN6/SHP-1 and PTPN11/SHP-2 (PubMed:10556798, PubMed:10206955, PubMed:10887109). In turn, these phosphatases regulate downstream pathways through dephosphorylation of signaling molecules (PubMed:10206955, PubMed:10887109). One of the repressive effect of CD33 on monocyte activation requires phosphoinositide 3-kinase/PI3K (PubMed:15597323)

The "CD33 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about CD33 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets

CD34 | CD36 | CD37 | CD38 | CD3D | CD3E | CD3G | CD4 | CD40 | CD40LG | CD44 | CD44-DT | CD46 | CD47 | CD48 | CD5 | CD52 | CD53 | CD55 | CD58 | CD59 | CD5L | CD6 | CD63 | CD68 | CD69 | CD7 | CD70 | CD72 | CD74 | CD79A | CD79B | CD8 | CD80 | CD81 | CD81-AS1 | CD82 | CD83 | CD84 | CD86 | CD8A | CD8B | CD8B2 | CD9 | CD93 | CD96 | CD99 | CD99L2 | CD99P1 | CDA | CDADC1 | CDAN1 | CDC123 | CDC14A | CDC14B | CDC14C | CDC16 | CDC20 | CDC20-DT | CDC20B | CDC20P1 | CDC23 | CDC25A | CDC25B | CDC25C | CDC26 | CDC27 | CDC27P2 | CDC34 | CDC37 | CDC37L1 | CDC37P1 | CDC40 | CDC42 | CDC42BPA | CDC42BPB | CDC42BPG | CDC42EP1 | CDC42EP2 | CDC42EP3 | CDC42EP4 | CDC42EP5 | CDC42SE1 | CDC42SE2 | CDC45 | CDC5L | CDC5L complex | CDC6 | CDC7 | CDC73 | CDCA2 | CDCA3 | CDCA4 | CDCA4P3 | CDCA5 | CDCA7 | CDCA7L | CDCA8 | CDCP1 | CDCP2